Background: To evaluate the prevalence of peripheral neuropathy associated with bortezomib
and its relation to multiple myeloma versus other malignancies.
Methods: This is a retrospective chart review study. Subjects who received bortezomib at HealthEast
Care System for various malignancies were evaluated. Statistical analyses were performed using SAS
Enterprise Guide software version 5.1. All comparison data were analyzed using Pearson’s Chi-Square.
Results: A total of 64 patients received bortezomib for various cancer and blood disorders. Two patients
were excluded from the analysis; one patient was diagnosed to have the possible POEMS syndrome and
another patient developed neuropathy after receiving multiple chemotherapy agents. Bortezomib related
neuropathy was seen in 46.8% (29 out of 62) of study patients. Neuropathy was higher in patients with
multiple myeloma (41.9%) vs. non-multiple myeloma (4.8%) with a p-value of 0.0091. The development
of peripheral neuropathy has no relation to age, gender, and prior neuropathy. Neuropathy developed in
75.9% of patients within four cycles of treatment (p=0.005).
Conclusion: Peripheral neuropathy is more common in multiple myeloma patients who received
bortezomib when compared with non multiple myeloma patients and develops in the first four cycles